Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission.
about
Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammationComorbidities in Cushing's diseaseThe Treatment of Cushing's Disease.The risks of overlooking the diagnosis of secreting pituitary adenomasCardiovascular consequences of cortisol excessA measure of glucocorticoid load provided by DNA methylation of Fkbp5 in miceExtended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.Resistant hypertension workup and approach to treatmentCardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging studyBoth transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-leiden.CETP miceCushing's syndrome: all variants, detection, and treatmentThe postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing's disease after transsphenoidal surgery.The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications.Discovery of adamantyl heterocyclic ketones as potent 11β-hydroxysteroid dehydrogenase type 1 inhibitorsAdamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1Neuropsychiatric disorders in Cushing's syndromeCushing's syndrome: epidemiology and developments in disease management.Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.Evaluation of Midnight Salivary Cortisol as a Predictor Factor for Common Carotid Arteries Intima Media Thickness in Patients with Clinically Inapparent Adrenal Adenomas.Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extensionTreatment of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineBody composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI.Vascular Dysfunction in Horses with Endocrinopathic Laminitis.Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.The effect of alpha-lipoic acid on mitochondrial superoxide and glucocorticoid-induced hypertension.A prospective study of appetite and food craving in 30 patients with Cushing's disease11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis.Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience.Modulatory effect of BclI GR gene polymorphisms on the obesity phenotype in Brazilian patients with Cushing's diseaseQuality of life and other outcomes in children treated for Cushing syndrome.Cushing's syndrome: aftermath of the cure.Blood pressure in pediatric patients with Cushing syndrome.Therapeutic manipulation of glucocorticoid metabolism in cardiovascular diseaseRelative growth hormone deficiency and cortisol excess are associated with increased cardiovascular risk markers in obese adolescent girls.Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study.Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.Pros and cons of screening for occult Cushing syndrome.
P2860
Q26998660-45F14D0D-85B7-43A8-9EA2-C4201616102CQ27010491-1F0FF6E0-3641-46D4-9B2C-5DD1D2730BDFQ27010590-44D75EF5-79D9-4DD3-B534-89B5980F756DQ28076665-693BD98C-04A1-4FA6-B983-1B13F4167E9AQ28289545-790F85B4-1E8A-4ECD-80AE-0CE760FF1966Q30571247-F092A53A-99EE-4BE2-821A-F64610F92DA2Q33858344-FDE5441D-826B-41AB-A720-2D5C33A44CA0Q34460704-B92E9313-C2B4-45F3-A592-7C7F18EBBEDCQ34468113-3B15FB6E-66BD-44F0-8BA9-C1E6336B944FQ34744777-DD545953-8BB4-4A96-89F5-9E0E17E9B479Q34984042-3BCAEAE7-554B-42CA-B621-FCE56FBAF269Q35101784-D0BD3E34-4384-40FB-8F10-85E686ACDF0AQ35126105-F38882E9-21D4-4F36-8362-49DAFBC56D46Q35207855-FF5188FF-594A-4E4C-928F-AF4B377FC479Q35231710-E78E32E8-6C5F-4AE4-BE01-8FB4E9159F75Q35487292-94484C6E-BFCE-406D-B00F-7BC86978F4D9Q35531889-BCD4E190-82BB-4466-B1AD-B55364363D99Q35582724-11D936A1-9D9F-4282-917D-4884AB2A75C0Q35657098-D0C21964-6264-4143-9FE9-A6FB8534AAE0Q35823679-9F4F69B9-A4BF-4493-96FF-372E68FFD184Q35916555-75AA63AE-451F-441E-A144-ADE13C2A2A91Q35921369-386B3FBC-E713-445C-AC92-36AD9C5E2E91Q36147976-E59F55EC-9FB9-4BD2-8B65-33601FDE31E5Q36266034-CBDA9B02-A342-4F5E-86F6-3523055024F6Q36402808-3011C6E0-4AFC-4A62-AC5E-08ACC41E6C63Q36692359-924A1A5C-B058-4CB0-9C9F-7A32B8818330Q36706264-7513FCF2-88B2-4D46-AADE-97BBBDE404EDQ36710876-7BFE6FFF-00CB-4101-B232-A860A086C904Q36800875-7F848168-B10A-4904-AF27-DF354AB599E8Q36844907-37D614F8-2F83-489B-B658-ACDC0CF5EA51Q36981968-33FBB87D-D813-4BCB-8BBC-1A0188706074Q37062081-835669B8-4E04-49EA-82C1-9494A2F2DABBQ37212316-4F5E93E2-70A0-4341-B0B9-4AB3A67017F4Q37230796-A9B7DA03-9F5F-4C81-9307-CFFBB3846FE3Q37315730-10198840-1252-4DEE-9B78-1747AE16C1A5Q37370170-20B972B4-8BEB-4484-9F1B-E272E0D012E8Q37422931-9E079DDE-B22E-4DCF-A0C8-EFA7566C5BE0Q37617500-71179EF4-7AF0-4525-B6F1-6D1D08B8B387Q37617588-7B40B8F3-2EE8-425F-A4AC-2FFF9021FD57Q37855520-EB127210-C519-413D-9ED8-2EDADD02F635
P2860
Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Cardiovascular risk factors an ...... year after disease remission.
@en
Cardiovascular risk factors an ...... year after disease remission.
@nl
type
label
Cardiovascular risk factors an ...... year after disease remission.
@en
Cardiovascular risk factors an ...... year after disease remission.
@nl
prefLabel
Cardiovascular risk factors an ...... year after disease remission.
@en
Cardiovascular risk factors an ...... year after disease remission.
@nl
P2093
P50
P356
P1476
Cardiovascular risk factors an ...... year after disease remission.
@en
P2093
Maria Cristina De Martino
Mariagiovanna Filippella
Stefano Spiezia
P304
P356
10.1210/JC.2002-021558
P407
P577
2003-06-01T00:00:00Z